VLPONC 01
Alternative Names: IL-12 saRNA; VLPONC-01; VRP-encapsulated saRNA encoding IL-12; VRP-IL-12Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator VLP Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; RNA
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Squamous cell cancer
Most Recent Events
- 23 Dec 2024 Preclinical trials in Squamous cell cancer in USA (Intratumoural) before December 2024 (VLP Therapeutics pipeline, December 2024)
- 16 Dec 2024 VLP Therapeutics plans a phase I trial for Squamous cell carcinoma (Recurrent, Metastatic disease) in USA (Intratumoral), (NCT06736379)